Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification  

作　　者：Yun Beom Sang Gwangil Kim Sohyun Hwang Haeyoun Kang Hong Jae Chon 

机构地区：[1]Department of Medical Oncology,CHA Bundang Medical Center,CHA University School of Medicine,Seongnam-si,Gyeonggi-do,Korea [2]Department of Pathology,CHA Bundang Medical Center,CHA University School of Medicine,Seongnam-si,Gyeo-nggi-do,Korea [3]CHA Future Medicine Research Institute,CHA Bundang Medical Center,Seongnam-si,Gyeonggi-do,Korea

出　　处：《Journal of Clinical and Translational Hepatology》2023年第3期747-750,共4页临床与转化肝病杂志（英文版）

基　　金：the National Research Founda-tion of Korea(NRF)grant funded by the Korea government(MSIT)(NRF-2020R1C1C1010722 to HJC).

摘　　要：We report a case of a patient with c-MET amplified hepato-cellular carcinoma (HCC) who had a dramatic response to cabozantinib despite being refractory to four previous lines of systemic therapy. The patient had previously received re-gorafenib plus nivolumab as first-line treatment, lenvatinib as second-line, sorafenib as third-line, and ipilimumab plus nivolumab as fourth-line treatment in sequence. However, all regimens showed early progression within 2 months. The pa-tient’s HCC was well-controlled, with a partial response (PR) of over 9 months after beginning cabozantinib treatment. Although there were mild adverse events such as diarrhea and elevated liver enzymes, they were tolerable. Next-gen-eration sequencing (NGS) of the patient’s previous surgical specimen indicated amplification of c-MET genes. Although it is well known that cabozantinib has excellent effectiveness for inhibiting c-MET at the preclinical level, to the best of our knowledge this is the first case of dramatic response to cabozantinib in a patient with advanced HCC with c-MET am-plification.

关 键 词：Hepatocellular carcinoma c-MET amplification Cabozantinib Dra-matic response Next-generation sequencing 

分 类 号：R735.7[医药卫生—肿瘤]